However, HDAC inhibitors in combination with ruxolitinib were not superior to ruxolitinib alone in recent phase 1/2 MPN clinicals trials (Bose et al., 2019; Mascarenhas et al., 2020). The gene discussed is HDAC9; the disease is myeloproliferative neoplasm.